Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

282 trials

NCT06898905
Recruiting
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
Not applicable · United States · 1 site
Registry update: 22 Jun 2026
NCT06176690
Recruiting
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Phase 1 · United States · 2 sites
Registry update: 2 Oct 2026
NCT06649812
Recruiting
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Phase 2 · United States · 115 sites
Registry update: 9 Nov 2026
NCT07200375
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Not applicable · China, Hong Kong · 22 sites
Registry update: 5 Nov 2026
NCT06931652
Recruiting
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
Phase 2 · France · 13 sites
Registry update: 15 Jun 2026
NCT07084662
Recruiting
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
Phase 2/3 · China · 1 site
Registry update: 26 Nov 2025
NCT07502118
Recruiting
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Phase 2/3 · 4 sites
Registry update: 30 Mar 2026
NCT06784726
Recruiting
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Phase 2 · United States · 1 site
Registry update: 28 Aug 2026
NCT06828991
Recruiting
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Phase 2 · United States · 1 site
Registry update: 20 Oct 2025
NCT07260812
Recruiting
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 1 · China · 1 site
Registry update: 26 Oct 2026
NCT06859008
Recruiting
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 · United States · 1 site
Registry update: 20 Apr 2026
NCT07059650
Recruiting
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
Phase 1/2 · China · 13 sites
Registry update: 1 Apr 2026
NCT06735664
Recruiting
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
Phase 1 · United States · 1 site
Registry update: 16 Sept 2026
NCT06854159
Recruiting
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
Phase 2 · United States · 1 site
Registry update: 8 Jul 2026
NCT07126236
Recruiting
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
Phase 2 · Spain · 19 sites
Registry update: 29 Sept 2026
NCT06905509
Recruiting
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Phase 2 · United States · 1 site
Registry update: 30 Jun 2026
NCT07124936
Recruiting
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Phase 1/2 · China · 21 sites
Registry update: 15 Aug 2025
NCT07065344
Recruiting
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
Not applicable · United Arab Emirates, Egypt, Iraq, Jordan, Kuwait, Morocco, Oman, Qatar, Saudi Arabia · 20 sites
Registry update: 23 Sept 2026
NCT07011056
Recruiting
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Phase 3 · China · 1 site
Registry update: 19 Sept 2025
2024-519318-30-00
Recruiting
Phase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell non-Hodgkin Lymphomas (CARMEN).
Phase 1 · Poland · 1 site
Registry update: 13 Mar 2026

Ordered by registry start date. Freshness and sponsorship never change the order.